Mutations in gonadotropin-releasing hormone signaling pathway in two nIHH patients with successful pregnancy outcomes by unknown
SHORT COMMUNICATION Open Access
Mutations in gonadotropin-releasing
hormone signaling pathway in two nIHH
patients with successful pregnancy
outcomes
Nikolay Zernov1, Mikhail Skoblov1,2,3, Ancha Baranova1,2,4,5* and Konstantin Boyarsky6,7
Abstract
Background: Anomalous levels of gonadotropin-releasing hormone (GnRH) secretion result in a variety of reproductive
phenotypes associated with infertility or subfertility. The normosmic isolated hypogonadotropic hypogonadism (nIHH) is
due to a failure of either GnRH pulsatile secretion in hypothalamus or its reception in pituitary. The spectrum of nIHH-
associated alterations continues to expand, especially when additional ethnic populations are investigated. The aim of this
study was to uncover genetic causes for nIHH in patients of Russian origin.
Methods: For two nIHH patients referred to infertility clinic, both exons and promoter sequences of 6 GnRH signaling
genes were sequenced.
Results: Patient 1 was a compound heterozygote for mutations in GnRH and its receptor encoding genes, while in
Patient 2 GnRHR mutations were found in homozygous state. In both patients, the coding frame of GnRHR gene
harbored missense-mutation Arg139His previously described as founder mutation in Polish and Brazilan patients. IVF/ET
treatments were successful, with phenotypically healthy offsprings delivered.
Conclusion: Polish founder mutation Arg139His in GnRHR was found in two nIHH patients originating from Western
region of Russia. Common variant of GnRH-encoding gene, Trp16Ser, could possibly contribute to reproductive
phenotypes in patients with heterozygous mutations of other GnRH signaling pathway genes.
Abbreviations: AMH, Anti-Mullerian hormone; FSH, Follicle stimulating hormone; GnRH, Gonadotropin-releasing
hormone; GnRHR, Gonadotropin-releasing hormone receptor; hCG, Human chorionic gonadotropin;
ICSI, Intracytoplasmic sperm injection; IVF/ET, In Vitro Fertilization/Embryo Transfer; KS, Kallmann syndrome;
LH, Luteinizing hormone; nIHH, Normosmic isolated hypogonadotropic hypogonadism; PCR, Polymerase chain
reaction; TSH, Thyroid-stimulating hormone.
Introduction
Despite the latest increase in the volume of relevant
publications, the majority of genetic variants influencing
sexual development and fertility remain either unknown
or poorly characterized in a majority of populations. The
secretion of gonadotropin-releasing hormone (GnRH) is
essential for the acquisition and maintenance of reproduct-
ive competence in mammals [1]. Importantly, anomalous
levels of GnRH secretion result in a variety of reproductive
phenotypes associated with infertility or subfertility.
Isolated hypogonadotropic hypogonadism, or isolated
gonadotropin-releasing deficiency, is relatively rare genetic
disease with an occurrence of about 1–10 cases per 100
000 births. In patients with isolated hypogonadotropic
hypogonadism, serum concentrations of FSH and LH are
low, while the levels of sex steroid are lacking and the
puberty is delayed in absence of any other pituitary defi-
ciencies. In about 60 % of these patients, the sense of smell
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is also impaired, producing either hyposmia or anosmia.
The latter condition is called Kallmann syndrome (KS).
Current classification of the KS includes 6 subtypes. X-
linked KS (type 1) is associated with KAL1 mutation,
while KS subtypes 2,3,4,5 and 6 are linked to the muta-
tions in genes FGFR1, PROKR2, PROK2, CHD7 and FGF8,
respectively [2, 3]. Patients with KAL1 mutation may also
have associated disorders of a neurological or urogenital
nature, thus, demonstrating more severe phenotype [1–3].
In the remaining 40 % patients, the sense of smell is
unchanged. The normosmic isolated hypogonadotropic
hypogonadism (nIHH) is due to a failure of either
gonadotropin-releasing hormone (GnRH) pulsatile
secretion in hypothalamus or its reception in pituitary.
In nIHH patients, causal mutations were identified in
genes GnRH1, GnRHR, KISS1, KISS1R, TAC3 and TAC3R
[2]. Importantly, the spectrum of nIHH-associated alter-
ations continues to expand, especially when additional eth-
nic populations are investigated.
Here we present our observations and successful treat-
ment of two non-consanguineous Russian female patients
diagnosed with nIHH. Prior to the referral to fertility clinic,
each patient underwent about 10 years of hormone replace-
ment therapy. In both patients, IVF/ET treatment was suc-
cessful, with phenotypically healthy offspring delivered. In
each patient, six candidate genes (GnRH1, GnRHR, KISS1,
KISS1R, TAC3, TAC3R) were analyzed by sequencing.
Patient 1 was a compound heterozygote for mutations in
gonadotropin-releasing hormone encoding gene (GnRH1)
and in gene encoding for its receptor (GnRHR), while in Pa-
tient 2 GnRHR mutations were found in homozygous state.
In both patients, the coding frame of GnRHR gene har-
bored missense-mutation Arg139His previously de-
scribed as founder mutation in Polish and Brazilan
patients (Beneduzzi D et al., 2014) and in some other unre-
lated patients across the globe (Laitinen EM et al, 2012).
Subjects and methods
Patients
Both patients were referred to infertility clinic due to pri-
mary amenorrhea in absence of eating disorders or strenu-
ous exercises, and infertility. Karyotypes were 46, XX, with
normal sense of smell. Both patients received hormone
replacement therapy with 2 mg oestradiol hemihydrate and
a combination of 2 mg oestradiol hemihydrate/10 mg
dydrogesterone (Femoston 2/10 mg, Abbott, Netherlands).
Other characteristics of the patients and the results of their
MRI and ultrasound examinations are shown in Table 1.
In vitro fertilization (IVF) with intracytoplasmic sperm
injection (ICSI)
In partners of both patients, the spermograms showed
insufficient sperm quality (Table 1), thus justifying in
vitro fertilization (IVF) with intracytoplasmic sperm in-
jection (ICSI).
In both patients, oocytes were obtained by standard
techniques within 36 h after administration of ovulatory
dose of hCG (10,000 IU, Pregnyl, MSD, Netherlands), by
follicle aspiration with 19G needle under ultrasound con-
trol. Obtained cumulus-oocyte complexes were placed in
culture media (Universal IVF Medium, Origio, Denmark)
for 2 h, then moved to medium containing recombinant
human hyaluronidase (ICSI Cumulase, Origio, Denmark)
for one minute, following by relocation into culture
medium. To estimate the quality of oocytes, their shape
and the presence of first polar body (metaphase II) were
assessed. Living sperm cells selected for ICSI were immobi-
lized in a drop of 10 % polyvinylpyrrolidone then injected
into oocyte located at position 6 or 12 o’clock.
DNA sequencing
Genomic DNA was isolated from the blood of two nIHH
patients using phenol-chloroform technique. Exonic and
promoter sequences for genes GNRH1 (NG_016457.1),
GNRHR (NG_009293.1), KISS1 (NG_032151.1), KISS1R
(NG_008277.1), TAC3 (NG_021398.1) and TAC3R
(NG_023344.1) were amplified by PCR using primers
located outside of intron-exon borders (Additional file
1: Table S1), the resultant PCR products were purified
with DyEx columns (QIAGEN) and bidirectionally
sequenced on the ABI PRISM®310 Genetic Analyzer
(Applied Biosystems). Sequence data were analyzed with
Chromas (Technelysium Pty.) software version 1.51 and
compared with the RefSeq sequences indicated above.
Ethical approval
Ethical approval was obtained from the local Institutional
Review Board at Department of Obstetrics and Gynecology,
State Pediatric Medical University, St.-Petersburg, Russia.
Results
Clinical outcomes
Upon initial nIHH diagnosis, both patients received
combined hormone replacement therapy. Table 2 lists en-
dogenous hormone values before the onset of reproduction
assistance treatments.
Patient 1
To correct the levels of TSH, patient received L-thyroxin
supplementation till her levels of TSH were brought to 2.8
nIU/ml. In IVF cycle, she received injections of human
menopausal gonadotropin (300 IU, Menopur, Ferring) for
11 days. After administration of human chorionic gonado-
tropin (Pregnyl, MSD) at a dose of 10000 IU, twelve oocytes
of good quality were retrieved. After fertilization by stand-
ard ICSI and 3 days of culture, two eight-cells embryos
were transferred to uterine cavity, while three remaining
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good quality embryos were frozen. One gestational sac was
detected in uterine cavity three weeks later.
After typical course of pregnancy, patient had uneventful
spontaneous delivery of a girl, at week 39, with birth weight
of 3150 g and length of 51 cm, Apgar scores were 9/9.
Patient 2
Ovarian stimulation was initiated with 225 IU of human
menopausal gonadotropin in daily injections for 13 days,
followed by induction of ovulation by human chorionic
gonadotropin (10000 IU). Five good quality oocytes were
retrieved. After conventional ICSI, two blastocysts of
good quality were transferred into uterine cavity, while
two remaining embryos were frozen. After four weeks, a
viable pregnancy was detected. At 9 weeks of gestation,
this pregnancy was lost. The cytogenetic analysis of
miscarried embryo showed normal karyotype 46, XX. Sub-
sequent transfer of frozen embryos was not successful.
One year after first attempt, another ovarian stimula-
tion was performed, with 300 IU of human menopausal
gonadotropin accompanied by FSH and LH for 15 days.
After total FSH dose of 4275 IU, three oocytes were
retrieved. After ICSI fertilization, two good quality embryos
(A8 and A6) were transferred in the uterus of the patient.
Early and mid-pregnancy course was typical. Patient
went into preterm birth due to placental abruption at
week 37. The delivery of a boy was by C-section. Weight
of a newborn was 3000 g, length was 50 cm, and Apgar
scores were 8/9.
Genetic analysis of the probands
Bidirectional sequencing was performed for 6 loci
(GnRH, GnRHR, KISS1, KISS1R, TAC3 and TAC3R) to
cover all exons and their borders. In both patients, the
mutations in GnRH and GnRHR genes were found
(Table 3). In Patient 1 genome, a compound heterozy-
gosity state was detected, with one copy of the GnRH1
gene exon 1 (g. G6757C; p. W16S) and one copy of GnRHR
gene exon 3 (g. C20426T; p. T269M) mutated. Additionally,
another mutation (g. G7167A; p. Arg139His) was identified
in exon 1 of the GnRHR gene in the same patient.
Table 2 Hormone values before the onset of reproduction
assistance treatments
Hormone Patient 1 Patient 2
1 attempt 2 attempt
FSH 0.1 IU/L 0.75 IU/L 0.3 IU/L
LH 0.1 IU/L 0.26 IU/L 0.1 IU/L
TSH 5.4 μIU/ml 1.34 μIU/ml 2.24 μIU/ml
Estradiol 12 pg/ml 12 pg/ml NA
Prolactin 202 mIU/ml 350 mIU/ml 153.8 mIU/ml
Inhibin B 8.8 pg/ml NA NA
AMH 0.1 ng/ml 1.96 ng/ml 0.93 ng/ml
FSH follicle stimulating hormone, LH luteinizing hormone, TSH thyroid-stimulating
hormone, AMH anti-mullerian hormone, NA not assayed
Table 1 Anthropometric and clinical characteristics of nIHH patients and their partners for IVF with ICSI
Characteristics Patient 1 Patient 2
Age at first visit to fertility clinic 28 years 31 years
Pubarche (spontaneous) at 14 years at 15 years
Heights 170 cm 156 cm
Weight 65 kg 53 kg
Breast development by Tanner scale Stage V Stage IV
Sense of odors Normal Normal
Karyotype 46, XX 46, XX
MRI of the pituitary Size: 10 mm x 6 mm x16 mm.
Signs of signal reduction in the
right half of the posterior pituitary
(4 mm x 3 mm x 2 mm), depicting
a cyst.
Size: 3.5 mm x 5 mm x 9 mm showing
signs of moderate pituitary hypoplasia
Vaginal ultrasound Uterus: 27 mm x 43 mm x 30 mm
Endometrium: 2.3 mm
Right ovary: 18 mm x 16 mm with
4 follicles (6 to 8 mm).
Left ovary: 17 mm x 18 mm with
5 follicles (6 to 7 mm).
Moderate hypoplasia of the
uterus and ovaries.
Uterus: 35 mm x 22 mm x30 mm
Endometrium: 1.8 mm
Right ovary: 21 mm x 18 mm
with 3 follicles (3 to 5 mm)
Left ovary: 17 mm x 18 mm with
5 follicles (6 to 7 mm). Moderate
hypoplasia of the ovaries.
Partner characteristics for IVF with ICSI Ejaculate volume: 2 ml
Sperm concentration: 39x106/ml,
Motile sperms: 3 %
Normal forms by Kruger strict criteria: 2 %.
Ejaculate volume: 5 ml
Sperm concentration: 31x106/ml
Motile sperms: None
Normal forms by Kruger strict criteria: 1 %.
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In patient 2, homozygous mutation in exon1 of the
GnRHR gene (g. G7167A; p. Arg139His) was detected
along with another homozygous intronic substitution
(g. T6891G).
No mutations were detected in exons or promoter
areas of KISS1, KISS1R, TAC3 and TAC3R.
The mutations contributing to nIHH condition of the
patients are summarized in Table 3 and Fig. 1 (a-c).
Genetic analysis of the relatives of probands
Affected exons of GnRH and GnRHR genes were bidir-
ectionaly sequenced in DNA samples in mothers and
live offsprings of both probands.
In the genome of mother of Patient 1, heterozygous mu-
tation of GNRHR exon 1 (g. 7167 G >A, rs104893842)
was found, while GNRHR exon 3 was mutation free. No
mutations were found in GNRH1 exon 1. Mother of Pa-
tient 2 was also heterozygous by GNRHR exon 1 mutation
(g. 7167 G > A, rs104893842). Mothers of both patients
were also homozygous for g.6891 T >G variant in gene
GNRH1 (rs2709608).
The genotype of the offspring of patient 1 was wild-
type for all informative loci, while the genome of the off-
spring of patient 2 carried heterozygous mutation g.
7167 G > A (rs104893842). In offspring, the state of the
g.6891 T > G polymorphism in gene GNRH1 (rs2709608)
was not assessed. Observed genotypes are described in
Table 3 and Fig. 1 (d, e).
Discussion
In this study, the GnRH1, GnRHR, KISS1, KISS1R, TAC3
and TAC3R genes were analyzed in two unrelated nIHH
patients successfully treated for infertility. In both pa-
tients, Arg139His substitutions were identified within
the receptor for hypothalamic gonadotropin-releasing
hormone. In patient 1, this mutation was found in het-
erozygous state, while patient 2 was homozygous. Muta-
tion p. Arg139His is located in a conserved DRS motif
between the third transmembrane loop and the second
intracellular loop. It completely inactivates the GnRH-
binding activity of the receptor and prevents GnRH-
induced stimulation of inositol phosphate accumulation
in vitro [4].
In a recent study of Choi et al., R139H mutation was
found to share a common founder core haplotype 220
kB in size. Interestingly, eight out of 15 carriers of this
founder haplotype were of Polish origin [5]. In our study,
both patients originated from Western region of Russia.
In particular, Patient 1 and her mother were born in
Pskov area that was under the winter-long siege by the
Polish Army during the final stage of the Livonian War
of 1558–1583. Hence, it is logical to conclude that p.
Arg139His most likely was inherited from Polish founders.
Also, it is tempting to speculate that R139 codon of
GNRHR gene is a hotspot region for receptor-inactivating
mutations, as the same codon was earlier found to contain
another p.R139C mutation identified in two unrelated
cases of Turkish origin [6, 7] and in Brazilian nIHH pa-
tients, where it was confirmed to associate with different
founder haplotype [8].
Interestingly, GNRHR gene of Patient 1 also possessed
a heterozygous T269M substitution that previously de-
scribed in ClinVar as pathogenic in a nIHH patient of
Asian/Indian origin. As the mother of patient 1 had no mu-
tation in this locus, this substitution should be of either
paternal origin or de novo. An absence of the mutation in
Patient’s 1 husband and offspring genotypes suggests that
Patient 1 genome is a cis-compound heterozygote for
R139H and T269M mutations. In turn, that means that
second allele of GNRHR in Patient 1 genome remains mu-
tation free, and that one copy of wild type allele able to
compensate for the deficiency of the receptor for GnRH
binding only partially, at least in presence of pituitary defi-
ciency and/or GnRH1 variant.
Indeed, the genome of Patient 1 had yet another het-
erozygous substitution, Trp16Ser [rs6185], in GnRH1.
This variant was previously reported as polymorphism
examined for its minor Ser16 allele association with
decreased bone mineral density [9] and shorter disease-
free survival in breast cancer patients [10]. Another recent
Table 3 The genotypes of the patients and their family members as assessed by bidirectional sequencing
Gene Family 1 Family 2
P1 P1’s mother P1’s offspring
(girl)
P2 P2’s mother P2’s offspring
(boy)
GNRH1 exon 1 g.6757 G > C rs6185
Heterozygous
wt wt wt wt wt
g.6891 T > G rs2709608
Homozygous intronic
variant
g.6891 T > G rs2709608
Homozygous intronic
variant
na g.6891 T > G rs2709608
Homozygous intronic
variant




GNRHR exon 1 g. 7167 G > A
rs104893842
Heterozygous
g. 7167 G > A
rs104893842
Heterozygous
wt g. 7167 G > A
rs104893842
Homozygous
g. 7167 G > A
rs104893842
Heterozygous
g. 7167 G > A
rs104893842
Heterozygous
GNRHR exon 3 g. 20426 C > T Heterozygous wt wt wt wt wt
P1 Patient 1, P2 Patient 2, wt wild-type, na not assessed
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study investigated this variant in polycystic ovarian
syndrome (PCOS) and showed that homozygous or
heterozygous carrier of Ser16 allele demonstrate some-
what more benign phenotype as compared with non-
carriers, with lower follicle counts, as well as lower
levels of testosterone, free androgen index and fasting
insulin [11]. On the other hand, the presence of Ser16
variant had no influence on gonadotrophic hormone
levels [11]. It would be tempting to speculate that
Ser16 variant of hypothalamic gonadotropin-releasing
hormone has lower potency than its wild-type variant,
and could be a contributing factor to the reproductive
phenotype of patient 1.
Importantly, reproductive interventions were successful
in both nIHH patients despite the presence of GnRH resist-
ance which is typical for women who have mutations in
GNRHR [3, 12]. In nIHH patients, decreased circulating
Anti-Mullerian Hormone (AMH) concentrations are not
indicative of a decreased follicular reserve. An adminis-
tration of human menopausal gonadotropin aids in
overcoming ovarian insufficiency by inducing matur-
ation of ovarian follicles. Women with nIHH should be
informed that their infertility is treatable. In cases of
homozygous founder mutations, mothers should be ad-
vised about the possibility that the chances for their off-
spring to inherit nIHH may increase if their partner
comes from the same geographical region. However,
the autosome recessive mode of inheritance along with
non-life threatening, treatable nature of the nIHH con-
dition make pre-implantation diagnostics unnecessary
in the majority of cases.
Conclusions
Polish founder mutation Arg139His in GnRHR was
found in two nIHH patients originating from Western
region of Russia. Common variant of GnRH-encoding
gene, Trp16Ser, could possibly contribute to reproductive
phenotypes in patients with heterozygous mutations of
other GnRH signaling pathway genes. Women with nIHH
should be informed that their infertility is treatable.
Fig. 1 Sanger sequencing chromatograms of mutated loci in patients and their family members. a Sequencing chromatogram of the exon 1 of
GNRH1 gene in Patient 1 and Patient 2 genomes. b Sequencing chromatogram of the exon 1 of GNRHR gene in Patient 1 and Patient 2
genomes. c Sequencing chromatogram of the exon 3 of GNRHR gene in Patient 1 genomes. d Sequencing chromatogram of the exon 1 of
GNRHR gene in the genomes of mothers of Patient 1 and Patient 2. e Sequencing chromatogram of the exon 1 of GNRHR gene in the genome
of Patient 1 offspring
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